Predictive value of serum iron on heart failure in patients with acute ST-segment elevation myocardial infarction

Wen Chen1, Guoli Lin1, Caizhi Dai1

  • 1Department of Cardiology, The Affiliated Hospital of Putian University, Putian University, Fujian, China.

Clinical Cardiology
|February 14, 2023
PubMed

Insights

Lower serum iron levels are a significant risk factor for developing heart failure after acute ST-segment elevation myocardial infarction (STEMI). Early prediction of heart failure post-STEMI may benefit from monitoring serum iron.

Area of Science:

  • Cardiology
  • Biomarkers
  • Clinical Medicine

Background:

  • Heart failure frequently complicates acute myocardial infarction, necessitating early predictive biomarkers.
  • Acute ST-segment elevation myocardial infarction (STEMI) is a critical condition often leading to heart failure.
  • Identifying novel biomarkers for early heart failure prediction post-STEMI is crucial for clinical practice.

Purpose of the Study:

  • To investigate the association between serum iron levels and the incidence of heart failure following STEMI.
  • To evaluate serum iron as a potential predictive biomarker for heart failure in STEMI patients.

Main Methods:

  • A cohort study included 41 patients with heart failure post-STEMI and 31 control subjects.
  • Demographic and clinical characteristics were analyzed.
  • Binary logistic regression and receiver operating characteristic (ROC) analyses were performed to assess predictive values.

Main Results:

  • Serum iron levels were significantly lower in patients with heart failure post-STEMI compared to controls.
  • Serum iron and Troponin I (Tn-I) were identified as independent predictors of heart failure post-STEMI.
  • ROC analysis indicated serum iron has a significant area under the curve (0.808), with an optimal cutoff of 11.87 μmol/L.

Conclusions:

  • Reduced serum iron levels are associated with an increased risk of heart failure after STEMI.
  • Serum iron serves as a potential independent risk factor and predictive biomarker for heart failure in STEMI patients.
  • Monitoring serum iron may aid in the early identification of patients at high risk for heart failure post-STEMI.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
219
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
19
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
24
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
134
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
43
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
46